{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T05:05:55Z","timestamp":1779253555935,"version":"3.51.4"},"reference-count":27,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J STD AIDS"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      <jats:italic toggle=\"yes\">Mycoplasma genitalium<\/jats:italic>\n                      is a sexually transmitted pathogen of public health concern due to antimicrobial resistance to the recommended first- and second-line treatments, azithromycin and moxifloxacin. The\n                      <jats:italic toggle=\"yes\">M. genitalium<\/jats:italic>\n                      Antimicrobial Resistance Surveillance (MARS) programme monitors resistance trends in England to inform clinical management and public health policy. Here, we summarise key findings from MARS 2024.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      From 1\n                      <jats:sup>st<\/jats:sup>\n                      March to 30\n                      <jats:sup>th<\/jats:sup>\n                      June 2024,\n                      <jats:italic toggle=\"yes\">M. genitalium<\/jats:italic>\n                      -positive specimens were collected at 32 sentinel sexual health services across England. Specimens were tested for molecular markers predictive of macrolide and fluoroquinolone resistance in the\n                      <jats:italic toggle=\"yes\">23S rRNA<\/jats:italic>\n                      and\n                      <jats:italic toggle=\"yes\">parC<\/jats:italic>\n                      genes, respectively. In non-wildtype\n                      <jats:italic toggle=\"yes\">parC<\/jats:italic>\n                      specimens, the\n                      <jats:italic toggle=\"yes\">gyrA<\/jats:italic>\n                      gene was also sequenced. AMR data were linked to patient demographic, clinical, and behavioural data.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The MARS 2024 sample included 1,049 individuals; 65.6% were male. Where resistance results were available, 63.6% of specimens were macrolide-resistant, 16.7% were fluoroquinolone resistant, and 13.7% were dual-resistant to both antimicrobials. Compared to MARS 2023, high levels of macrolide resistance remain, with increasing fluoroquinolone (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.008) and dual resistance (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.024).\n                    <\/jats:p>\n                    <jats:p>Most individuals (87.3%) were prescribed the recommended first- or second-line treatments and 80.8% received doxycycline as a pre-treatment. Resistant genotypes were common among those with a positive test-of-cure (TOC): 90.9% of individuals with a positive TOC following azithromycin were infected with a macrolide-resistant strain, and 51.6% of those with a positive TOC following moxifloxacin were infected with a fluoroquinolone-resistant strain. However, genotype did not consistently predict TOC outcome, as 14.6% of those with negative TOCs following azithromycin had macrolide-resistant infections and 16.6% of those with negative TOCs following moxifloxacin had fluoroquinolone-resistant infections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      MARS 2024 is the largest dataset examining antimicrobial resistance in\n                      <jats:italic toggle=\"yes\">M. genitalium<\/jats:italic>\n                      in England, confirming widespread macrolide resistance and increasing levels of fluoroquinolone and dual resistance, underscoring the importance of national surveillance to inform management guidelines.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/09564624261436151","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T07:45:01Z","timestamp":1774338301000},"page":"768-777","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Key findings from the 2024\n                    <i>Mycoplasma genitalium<\/i>\n                    Antimicrobial Resistance Surveillance (MARS) programme"],"prefix":"10.1177","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4730-4779","authenticated-orcid":false,"given":"Kirsty F.","family":"Bennet","sequence":"first","affiliation":[{"name":"UK Health Security Agency"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James E. C.","family":"Johnson","sequence":"additional","affiliation":[{"name":"UK Health Security Agency"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandhya","family":"Vivekanand","sequence":"additional","affiliation":[{"name":"UK Health Security Agency"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"David","sequence":"additional","affiliation":[{"name":"UK Health Security Agency"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Penelope","family":"Cliff","sequence":"additional","affiliation":[{"name":"UK Health Security Agency"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Vickers","sequence":"additional","affiliation":[{"name":"UK Health Security Agency"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Pitt-Kendall","sequence":"additional","affiliation":[{"name":"UK Health Security Agency"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Callan","sequence":"additional","affiliation":[{"name":"UK Health Security Agency"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katy","family":"Sinka","sequence":"additional","affiliation":[{"name":"UK Health Security Agency"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamish","family":"Mohammed","sequence":"additional","affiliation":[{"name":"UK Health Security Agency"},{"name":"University College London in Partnership with the UK Health Security Agency"},{"name":"University College London"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Alexander","sequence":"additional","affiliation":[{"name":"UK Health Security Agency"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Fifer","sequence":"additional","affiliation":[{"name":"UK Health Security Agency"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle J.","family":"Cole","sequence":"additional","affiliation":[{"name":"UK Health Security Agency"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2023.02.009"},{"key":"e_1_3_3_3_2","doi-asserted-by":"crossref","unstructured":"Soni S Fifer H Al-Shakarchi Y et al. British Association of Sexual Health and HIV National guideline for the management of infection with Mycoplasma genitalium 2025. Int J STD AIDS. 2025 Epub ahead of print. https:\/\/doi.org\/10.1177\/09564624251359054","DOI":"10.1177\/09564624251359054"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2017-053384"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy477"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ644"},{"issue":"7","key":"e_1_3_3_7_2","first-page":"435","article-title":"Antimicrobial treatment and resistance in sexually transmitted bacterial infections","volume":"22","author":"Jensen JS","year":"2024","unstructured":"Jensen JS, Unemo M. Antimicrobial treatment and resistance in sexually transmitted bacterial infections. Nat Rev. 2024; 22(7): 435\u2013450. https:\/\/doi.org\/10.1038\/s41579-024-01023-3","journal-title":"Nat Rev"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1086\/593188"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanmic.2024.101047"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/48.5.742"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2305.161745"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198355"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad057"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/0956462419825948"},{"key":"e_1_3_3_15_2","volume-title":"Mycoplasma genitalium Antimicrobial Resistance Surveillance (MARS) report: 2023","author":"UK Health Security Agency","year":"2024","unstructured":"UK Health Security Agency. Mycoplasma genitalium Antimicrobial Resistance Surveillance (MARS) report: 2023, 2024."},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.2.683-692.2004"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.7.3121-3128.2005"},{"key":"e_1_3_3_18_2","unstructured":"Bogart S. SankeyMATIC. [Online]. Available. https:\/\/sankeymatic.com\/ (2014 Accessed 2025)."},{"key":"e_1_3_3_19_2","volume-title":"Mycoplasma genitalium Antimicrobial Resistance Surveillance (MARS) report: 2024","author":"UK Health Security Agency","year":"2025","unstructured":"UK Health Security Agency. Mycoplasma genitalium Antimicrobial Resistance Surveillance (MARS) report: 2024. UKHSA, 2025."},{"key":"e_1_3_3_20_2","unstructured":"Office for National Statistics. List of ethnic groups. [Online]. Available. https:\/\/www.ethnicity-facts-figures.service.gov.uk\/style-guide\/ethnic-groups\/ (2025 Accessed 2025)."},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0b013e31828bfccf"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa293"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0000000000001591"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-024-02261-6"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv246"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00278-22"},{"issue":"4","key":"e_1_3_3_27_2","first-page":"71","article-title":"OA14.02 \u2013 Revealing the Importance of gyrA, gyrB, parC and parE Genes Against Fluoroquinolone Resistance in Mycoplasma genitalium by in Vitro Selection [Conference abstract]","volume":"22","author":"Doelman T","year":"2025","unstructured":"Doelman T, Adriaens N, Bhaggan A, et al. OA14.02 \u2013 Revealing the Importance of gyrA, gyrB, parC and parE Genes Against Fluoroquinolone Resistance in Mycoplasma genitalium by in Vitro Selection [Conference abstract]. Sexual Health. 2025; 22(4): 71. https:\/\/doi.org\/10.1071\/SHv22n4abs","journal-title":"Sexual Health"},{"issue":"1","key":"e_1_3_3_28_2","first-page":"48","article-title":"P0014 - Mycoplasma genitalium diagnoses in England 2015 to 2023, a descriptive study [Conference abstract]","volume":"36","author":"Johnson JEC","year":"2025","unstructured":"Johnson JEC, Bennet KF, Baldry G, et al. P0014 - Mycoplasma genitalium diagnoses in England 2015 to 2023, a descriptive study [Conference abstract]. Int J STD AIDS. 2025; 36(1): 48\u201349. https:\/\/doi.org\/10.1177\/09564624251339054","journal-title":"Int J STD AIDS"}],"container-title":["International Journal of STD &amp; AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09564624261436151","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/09564624261436151","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09564624261436151","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:08:09Z","timestamp":1779250089000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/09564624261436151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1177\/09564624261436151"],"URL":"https:\/\/doi.org\/10.1177\/09564624261436151","relation":{},"ISSN":["0956-4624","1758-1052"],"issn-type":[{"value":"0956-4624","type":"print"},{"value":"1758-1052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]}}}